Danaher Corporation
DHR
$203.83
-0.58%
Danaher Corporation is a global science and technology innovator that designs, manufactures, and markets professional, medical, industrial, and commercial products and services, primarily in the life sciences and diagnostics industries. As a market leader in scientific instrumentation and consumables, Danaher distinguishes itself through its renowned Danaher Business System (DBS) for continuous improvement and a disciplined acquisition strategy. The current investor narrative centers on the company's post-Veralto divestiture transformation, its strategic acquisition of Masimo, and a recent 36% decline from peak levels that has sparked debate about whether the stock offers a compelling value opportunity amid a recovery in its core businesses.…
DHR
Danaher Corporation
$203.83
Related headlines
DHR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Danaher Corporation's 12-month outlook, with a consensus price target around $242.52 and implied upside of +19.0% versus the current price.
Average Target
$242.52
0 analysts
Implied Upside
+19.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$200 - $310
Analyst target range
Danaher is covered by 23 analysts, with a consensus recommendation of 'Strong Buy' (mean score 1.5 on a 1-5 scale). The average price target is $242.52, implying approximately 19% upside from the current price of $203.83. The distribution shows 1 Strong Buy, 0 Buy, 0 Hold, 0 Sell, and 0 Strong Sell (based on the recommendation mean of 1.5, which typically corresponds to a Buy rating). The consensus leans strongly bullish, reflecting confidence in the company's growth trajectory and strategic moves. The target price range spans from a low of $200.00 to a high of $310.00. The low target of $200.00 is slightly below the current price, suggesting that even the most bearish analyst sees limited downside, while the high target of $310.00 implies over 52% upside, likely assuming successful integration of Masimo and margin expansion. The wide spread ($110) indicates significant uncertainty about the pace of recovery and deal benefits. Recent institutional ratings show mostly positive actions: Evercore ISI (Outperform), HSBC (Buy), Morgan Stanley (Overweight), and UBS (Buy), though Citigroup downgraded from Buy to Neutral in May 2026. The overall sentiment remains bullish, but the downgrade highlights some caution on near-term execution.
Drowning in data?
Find the real signal!
DHR Technical Analysis
Danaher is in a recovery phase after a prolonged downtrend, with the stock trading at $203.83, up 4.64% over the past year but still 16.1% below its 52-week high of $242.80. The current price sits at 77.4% of the 52-week range (from low of $160.93 to high of $242.80), indicating it has bounced off the lows but remains well below the peak, suggesting cautious optimism rather than full momentum. The 1-year price change of +4.64% underperforms the S&P 500's +18.35%, reflecting the stock's relative weakness over the longer term. Short-term momentum has turned decisively positive: the 1-month price change is +14.67% versus the S&P 500's +0.31%, a relative strength of +14.36%. The 3-month change of +4.66% also outpaces the index's +4.67% marginally, but the 6-month change of -13.63% versus the S&P 500's +7.46% shows the recovery is recent. This divergence—strong 1-month momentum against a weak 6-month trend—suggests a potential trend reversal or mean reversion rally, supported by the stock's bounce from its May 2026 low near $161. The 52-week low of $160.93 provides a key support level, while the 52-week high of $242.80 is the primary resistance. A breakout above $242.80 would signal a resumption of the long-term uptrend, while a breakdown below $160.93 could indicate further downside. With a beta of 0.823, Danaher is less volatile than the overall market, meaning it tends to decline less in downturns but also lag in strong rallies, which is consistent with its defensive healthcare positioning.
Beta
0.82
0.82x market volatility
Max Drawdown
-33.1%
Largest decline past year
52-Week Range
$161-$243
Price range past year
Annual Return
+4.6%
Cumulative gain past year
| Period | DHR Return | S&P 500 |
|---|---|---|
| 1m | +14.7% | -0.5% |
| 3m | +4.7% | +4.9% |
| 6m | -13.6% | +9.7% |
| 1y | +4.6% | +18.4% |
| ytd | -11.5% | +9.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DHR Fundamental Analysis
Danaher's revenue trajectory shows modest but steady growth, with Q1 2026 revenue of $5.951 billion, up 3.66% year-over-year from $5.741 billion in Q1 2025. However, the multi-quarter trend reveals deceleration: Q4 2025 revenue was $6.838 billion (up 4.6% YoY from $6.538 billion), while Q3 2025 revenue of $6.053 billion was up 4.4% from $5.798 billion. The recurring revenue segment, at $5.031 billion, dominates the $5.951 billion total, indicating a stable base, while nonrecurring revenue of $0.92 billion adds variability. The growth rate, while positive, is modest for a healthcare technology company, and the investment case hinges on whether the Masimo acquisition and life sciences recovery can accelerate top-line expansion. Profitability remains solid: Q1 2026 net income was $1.029 billion, with a net margin of 17.3%, up from 16.6% in Q1 2025. Gross margin improved to 60.3% from 61.4% in the prior year quarter, while operating margin was 22.6% versus 22.5% a year ago. The trailing twelve-month free cash flow of $5.291 billion is robust, and the company's ability to generate cash supports its acquisition strategy and dividend. Danaher's balance sheet is healthy: the debt-to-equity ratio is 0.35, and the current ratio of 1.87 indicates ample liquidity. Free cash flow per share (TTM) is approximately $7.48, and the company generated $1.322 billion in operating cash flow in Q1 2026, more than covering capital expenditures of $237 million. The ROE of 6.88% and ROA of 4.19% are moderate but reflect the capital-intensive nature of the business and the impact of recent acquisitions.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+3.7%
YoY Comparison
Gross Margin
60.3%
Latest Quarter
Free Cash Flow
$5.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DHR Overvalued?
Since Danaher has positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 45.15x, while the forward P/E is 22.06x, implying that the market expects significant earnings growth in the next year. The wide gap between trailing and forward P/E suggests that the market is pricing in a sharp earnings recovery, likely driven by cost synergies from the Masimo acquisition and operational improvements. Compared to the industry (Medical - Diagnostics & Research), Danaher's trailing P/E of 45.15x is at a premium to the sector average (not provided, but typically in the 20-30x range). The forward P/E of 22.06x is more in line with industry norms, indicating that the premium is largely due to depressed trailing earnings. Historically, Danaher's trailing P/E has ranged from roughly 19x to 64x over the past five years. The current 45.15x is above the midpoint of that range, suggesting the stock is not cheap on a trailing basis, but the forward multiple of 22.06x is near the lower end of its historical forward P/E band (typically 20-30x), implying that if earnings materialize as expected, the valuation is reasonable. The PEG ratio of -9.26 is negative due to negative earnings growth expectations (likely from acquisition-related charges), making it less useful.
PE
45.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 19x~51x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
25.3x
Enterprise Value Multiple
